KINAXO Extends Collaboration with Takeda
KINAXO Biotechnologies GmbH announced that it has entered a second collaboration with Takeda Pharmaceutical Company Limited Osaka, Japan. Under the agreement KINAXO will apply its quantitative phosphoproteomics technology PhosphoScout® to assist in research of drugs under development at Takeda. This will allow Takeda to take early educated decisions on drug efficacy and safety. Financial details of the agreement were not disclosed.
Dr. Andreas Jenne, KINAXO’s CEO said: “We are very pleased to continue our collaboration with Takeda, a world leading healthcare company, and look forward to supporting Takeda’s efforts in developing drugs. This collaboration once again demonstrates the power of our PhosphoScout® platform in drug discovery and development.”
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.